Executive Summary : | COVID-19, caused by SARS-CoV 2, is a highly dangerous infectious disease that has resulted in 63.24 lakh deaths worldwide and 5.25 lakh deaths in India up to June 2022. The World Health Organization (WHO) reported that there were 539.9 crore confirmed cases globally, with India being the second most affected country with 8.56 crore cases. Vaccines are believed to be the promising way to end the pandemic, with 11.91 billion doses administered worldwide and 1.97 billion doses attained in India until June 2022. However, vaccines face challenges such as bulk production issues, stability, cold chain supply, storage facilities, trained personnel, pain during administration, and patient compliance. Nano-vaccines, a novel category of vaccines using nanoparticles as carriers, can improve immunogenecity but also face problems like bulk production issues, stability, cold chain supply, storage facilities, trained personnel, pain during administration, and patient compliance. This research work proposes the development of nano-vaccine and its painless smart delivery using microneedles through transcutaneous routes. This technology combines the higher immunogenic potential of nano-vaccine and microneedle, minimizing or alleviating problems associated with conventional vaccines. The nano-vaccine enhances the stability of the macromolecule, reducing wastage and reducing the need for refrigerated storage and cold supply chains. Additionally, the microneedles are not painful, alleviating patient fear of pain during administration and needle stick injury, leading to increased patient compliance. |